Clinical effects of autologous stem cell transplantation as consolidation treatment in 70 multiple myeloma patients： a case-controlled study

• Published in: Chinese medical journal Vol. 124; no. 19; pp. 2975 - 2980
• Main Authors: Zhou, Li-Li, Yuan, Zhen-Gang, Fu, Wei-Jun, Xi, Hao, Zhang, Chun-Yang, Lan, Hai-Feng, Zhang, Xin, Chen, Yu, Liu, Wen-Yu, Hou, Jian
• Format: Journal Article
• Language: English
• Published: China Division of Hematology Changzheng Hospital, Second Millitary Medical University, Shanghai 200003, China%Eight-year Program MD Changzheng Hospital, Second Millitary Medical University, Shanghai 200003, China 01.10.2011
• Subjects: Adult; Female; Humans; Male; Middle Aged; Multiple Myeloma - therapy; Prognosis; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; 临床疗效; 单因素分析; 多发性骨髓瘤; 患者; 治疗效果; 病例; 自体; 造血干细胞移植; hematopoietic stem cell transplantation; multiple myeloma; prognosis; survival
• ISSN: 0366-6999; 2542-5641; 2542-5641
• DOI: 10.3760/cma.j.issn.0366-6999.2011.19.003

Background Autologous stem cell transplantation （ASCT） is a part of the standard induction therapy of multiple myeloma （MM）. This case-controlled clinical trial aimed to further evaluate the therapeutic effects of ASCT as a consolidation therapy for MM and discuss factors influencing the prognosis.Methods Clinical data of 70 patients diagnosed as MM who received ASCT as a consolidation therapy in our hospital between October 1998 and August 2010 were analyzed retrospectively （ASCT group）. Other 70 MM patients receiving routine chemotherapy without ASCT （non-ASCT group） during the same period were used as controls. Differences in the degree and duration of remission, progression-free survival （PFS） and overall survival （OS） were compared to explore factors that may influence the prognosis.Results The median follow-up period was 38 months （range 1-128 months）. The complete response （CR） rate of ASCT group increased from 27.1% （19/70） before ASCT to 51.4% （36/70） after ASCT. The median PFS of ASCT group was significantly higher than non-ASCT group （45 months vs. 25 months, P 〈0.001）. The median OS of ASCT group was also significantly higher （55 months vs. 30 months, P=0.016）. Single-factor analysis showed that International Staging System （ISS） stage, very good partial response （VGPR） or better outcome were significantly correlated with PFS and OS （P 〈0.001）. Multi-factor analysis showed that whether or not VGPR or better outcome was achieved were independent factors influencing the disease prognosis.Conclusion Used as a consolidation therapy, ASCT can achieve better responses and higher OS and PFS of MM patients.